circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
== Places == Garsdale railway station, England (GB CRS code) Georgia School for the Deaf, Cave Spring, Georgia, United States Harvard Graduate School of Design, Gund Hall, Cambridge, Massachusetts, US
=== Pleiotropy-barrier model === The 'pleiotropy-barrier' model suggests that newly evolved genes, including de novo genes and duplication-related genes, could facilitate evolutionary innovation or evolution of specific functions due to their low (or no) pleiotropic effect, when facing new selective force, based on observations from human gene-disease data.
=== Failed proposed changes === 2015: Proposals to amalgamate local councils in Wellington and Northland were accepted by the Local Government Commission for consideration, although following consultation they ultimately were not formed into a final proposal. The status quo remains. 2015: Amalgamation of four local councils and the regional council in Hawke's Bay was proposed by the Local Government Commission. A district wide referendum was held in Sep-2015, and the proposal was defeated by 66% of voters. 2015: The Local Government Commission received a proposal to review local government arrangements on the West Coast. In August 2016 the Commission decided to progress the application. The Commission then invited alternative applications to the original application. The Commission's call for alternative reorganisation applications or other proposals for change to West Coast local government arrangements closed on 15 March 2017. The Commission received 23 responses, 19 of which made specific proposals for change. In December 2017 the Local Government Commission determined its preferred option for local government reorganisation on the West Coast to be the transfer of district plan preparation from the Buller, Grey and Westland district councils to the West Coast Regional Council. 2017: The Local Government Commission received a proposal to amalgamate the Masterton, Carterton and South Wairarapa District Councils into a combined Wairarapa District Council. The proposal was defeated by referendum with 59% of voters rejecting the proposed merger.
Sources: en.wikipedia.org
Zita of Bourbon-Parma (Zita Maria delle Grazie Adelgonda Micaela Raffaela Gabriella Giuseppina Antonia Luisa Agnese; 9 May 1892 – 14 March 1989) was the last Empress of Austria and Queen of Hungary, in addition to other titles. She ascended to these titles when her husband, Charles I, became the last monarch of Austria-Hungary. She was declared Servant of God by Pope Benedict XVI. Born as the seventeenth child of the dispossessed Robert I, Duke of Parma, by his second wife, Infanta Maria Antonia of Portugal, Zita married Archduke Charles of Austria in 1911. Charles became heir presumptive to Emperor Franz Joseph I in 1914 after the assassination of his uncle Archduke Franz Ferdinand of Austria, and acceded to the throne in 1916 after the elderly emperor's death. After the end of World War I in 1918, the Habsburgs were deposed and the former empire became home to the states of Austria, Hungary, and Czechoslovakia, while other parts were annexed to or joined the Kingdom of the Serbs, Croats and Slovenes, Italy, Romania, and a reconstituted independent Poland. Charles and Zita left for exile in Switzerland and, after the failure of attempts to restore royal rule in Hungary, were subsequently removed from that country by the Allies to Madeira, where Charles died in 1922. After her husband's death, Zita and her son Otto served as symbols of unity for the exiled dynasty. A devout Catholic, she raised a large family after being widowed at the age of 29; she never remarried.
As with the farming of terrestrial animals, social attitudes influence the need for humane practices and regulations in farmed marine animals. Under the guidelines advised by the Farm Animal Welfare Council good animal welfare means both fitness and a sense of well-being in the animal's physical and mental state. This can be defined by the Five Freedoms:
Furthermore, specific LTBP isoforms have a propensity to associate with specific LAP•TGF-β isoforms. For example, LTBP-4 is reported to bind only to TGF-β1, thus, mutation in LTBP-4 can lead to TGF-β associated complications which are specific to tissues that predominantly involves TGF-β1. Moreover, the structural differences within the LAP's provide different latent TGF-β complexes which are selective but to specific stimuli generated by specific activators.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.